<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786265</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0993</org_study_id>
    <secondary_id>NCI-2018-01856</secondary_id>
    <secondary_id>2012-0993</secondary_id>
    <nct_id>NCT01786265</nct_id>
  </id_info>
  <brief_title>Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Participants With Recurrent Prostate Cancer</brief_title>
  <official_title>A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well finite androgen ablation with or without abiraterone
      acetate and prednisone work in treating participants with prostate cancer that has come back.
      Androgen can cause the growth of prostate cancer cells. Hormone therapy, such as finite
      androgen ablation, using leuprolide acetate, goserelin acetate, degarelix, bicalutamide,
      flutamide, and nilutamide may fight prostate cancer by lowering the amount of androgen the
      body makes. Abiraterone acetate may help to decrease the production of testosterone, and
      prednisone may help lower or prevent some side effects. It is not yet known whether giving
      acetate, goserelin acetate, degarelix, bicalutamide, flutamide, and nilutamide with or
      without abiraterone acetate and prednisone may work better in treating patients with prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate whether finite maximal androgen ablation (8 month), as compared to
      luteinizing-hormone-releasing hormone (LHRH) alone, will improve one-year post-treatment
      prostate specific antigen (PSA)-free survival by 20%.

      SECONDARY OBJECTIVES:

      I. To determine testosterone recovery difference between the two groups. II. Calculate the
      PSA-free survival following testosterone recovery. III. To determine in the steroid
      biosynthesis metabolome, in the blood and bone marrow of patients at baseline, maximum
      response (eight months therapy) and upon PSA progression, evidence of minimal residual cancer
      (MD Anderson Cancer Center [MDACC] main campus patients only).

      IV. To apply technologies in development able to detect presence of cancer cells (&quot;minimal
      residual disease&quot;) at a clinical study milestone (baseline, completion of therapy and upon
      PSA progression).

      EXPLORATORY OBJECTIVE:

      I. To explore in archival tissue samples for a candidate predictive signature of outcome
      applying technologies for interrogation of protein deoxyribonucleic acid (dna) and
      ribonucleic acid (rna) levels of molecular markers / pathways of interest.

      OUTLINE: Participants are randomized to 1 of 2 arms.

      ARM A: Participants receive either leuprolide acetate via injection every month or every 4
      months, goserelin acetate via injection every month, or degarelix via injection every month
      for 8 months. Participants also receive bicalutamide orally (PO) once daily (QD), flutamide
      PO three times daily (TID), or nilutamide PO QD. Participants may crossover to Arm B with
      disease progression after 8 months.

      ARM B: Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide,
      flutamide, or nilutamide as in Arm A. Participants also receive abiraterone acetate PO daily
      for 8 months and prednisone daily. Participants may crossover to Arm A with disease
      progression after 8 months.

      After completion of study treatment, participants are followed up every 3 and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2013</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) free survival (PSA &lt; 0.1 ng/ml)</measure>
    <time_frame>At 12 months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive either leuprolide acetate via injection every month or every 4 months, goserelin acetate via injection every month, or degarelix via injection every month for 8 months. Patients also receive bicalutamide PO QD, flutamide PO TID, or nilutamide PO QD. Patients may crossover to Arm B with disease progression after 8 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for 8 months and prednisone daily. Patients may crossover to Arm A with disease progression after 8 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>Casodex</other_name>
    <other_name>Cosudex</other_name>
    <other_name>ICI 176,334</other_name>
    <other_name>ICI 176334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>4''-Nitro-3''-trifluoromethylisobutyranilide</other_name>
    <other_name>Apimid</other_name>
    <other_name>Cebatrol</other_name>
    <other_name>Chimax</other_name>
    <other_name>Cytomid</other_name>
    <other_name>Drogenil</other_name>
    <other_name>Euflex</other_name>
    <other_name>Eulexine</other_name>
    <other_name>Flucinom</other_name>
    <other_name>Flucinome</other_name>
    <other_name>Flugerel</other_name>
    <other_name>Fluken</other_name>
    <other_name>Flulem</other_name>
    <other_name>FLUT</other_name>
    <other_name>Fluta-Gry</other_name>
    <other_name>Flutabene</other_name>
    <other_name>Flutacan</other_name>
    <other_name>Flutamex</other_name>
    <other_name>Flutamin</other_name>
    <other_name>Flutan</other_name>
    <other_name>Flutaplex</other_name>
    <other_name>Fugerel</other_name>
    <other_name>Grisetin</other_name>
    <other_name>Niftolide</other_name>
    <other_name>Oncosal</other_name>
    <other_name>Profamid</other_name>
    <other_name>Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-</other_name>
    <other_name>Prostacur</other_name>
    <other_name>Prostadirex</other_name>
    <other_name>Prostica</other_name>
    <other_name>Prostogenat</other_name>
    <other_name>Sch 13521</other_name>
    <other_name>Tafenil</other_name>
    <other_name>Tecnoflut</other_name>
    <other_name>Testotard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Lutrate</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>Anandron</other_name>
    <other_name>Nilandron</other_name>
    <other_name>RU-23908</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed an informed consent document indicating that the subjects understand the
             purpose of and procedures required for the study and are willing to participate in the
             study

          -  Written Authorization for Use and Release of Health and Research Study Information has
             been obtained

          -  Be willing/able to adhere to the prohibitions and restrictions specified in this
             protocol

          -  Life expectancy &gt;= 12 months

          -  ECOG performance status (PS) =&lt; 2

          -  Histologically documented diagnosis of adenocarcinoma of the prostate (PCa) with no
             histologic variants

          -  Prostate cancer recurrence after definitive local therapy (radical prostatectomy
             and/or radiation therapy) as evidenced by rising serum PSA, without evidence of
             metastases by bone scan or computed tomography (CT) scan

               -  After radiation: A rising PSA taken to indicate recurrent prostate cancer in
                  patients with previous definitive external beam radiotherapy will be defined as
                  PSA of 1.0

               -  After Radical Prostatectomy: A rising PSA taken to indicate recurrent prostate
                  cancer in patients with previous radical prostatectomy will be defined by the
                  criteria of the American Urological Association as any PSA measurement of 0.2,
                  with a subsequent measurement &gt; 0.2 ng/mL

          -  Patients who have received androgen ablative therapy for less than 8 weeks immediately
             prior to initiation of study drug are eligible provided they had only PSA evidence of
             progression (as defined above) with no visible metastases by CT-scan and bone scan
             (within 6 weeks) prior to starting androgen ablation

          -  White blood cell (WBC) &gt;= 3.5 x 10^9/L

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Platelets &gt;= 100 x 10^9/L

          -  Hemoglobin (Hb) &gt;= 9.0 g/dL

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 1.5 x the upper
             limit of normal

          -  Serum potassium of &gt;= 3.5 mEq/L

          -  Serum albumin of &gt;= 3.0 g/dL

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Patients must have recovered from prior treatment regimens, e.g. surgery, radiation

          -  A patient who is sexually active and their partner must agree and use two reliable
             barrier forms of contraception (for example, condoms and diaphragm), from first day of
             study drug administration until for 1 week after last dose of abiraterone acetate,
             unless partner is post-menopausal

          -  Able to swallow the study drug whole as a tablet

          -  Willing to take abiraterone acetate on an empty stomach; no food should be consumed at
             least two hours before and for at least one hour after the dose of abiraterone acetate
             is taken

        Exclusion Criteria:

          -  Patients who have received prior hormonal therapy are excluded from the trial, except
             for: patients who have received up to 6 months of hormonal therapy as neoadjuvant
             therapy before radical prostatectomy or while on radiation therapy, as long as more
             than 1 year has elapsed between discontinuation of the neoadjuvant hormonal therapy
             and initiation of hormonal treatment for relapsing disease

          -  Any known metastases

          -  Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt;= 450 msec)

          -  Clinically significant heart disease as evidenced by myocardial infarction, or
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction
             measurement of &lt; 50% at baseline

          -  Significant co-morbidity that could affect the safety or evaluability of participants
             as assessed by the treating physician and or principal investigator

          -  Prior therapy with strontium-89, samarium, rhenium-186 etidronate, chemotherapy or
             androgen biosynthesis inhibitors for prostate cancer is not allowed. Previous
             immunologic, homeopathic, natural, or alternative medicine therapies are acceptable
             provided treatment ended greater than 28 days prior to initiation of study drug

          -  Patients who, in the opinion of the investigator, are unable to comply with the
             requirements of the study protocol are not eligible

          -  Active infection or other medical condition that would make prednisone/prednisolone
             (corticosteroid) use contraindicated

          -  Active or symptomatic viral hepatitis

          -  History of pituitary or adrenal dysfunction

          -  Administration of an investigational therapeutic drug within 30 days of cycle 1 day 1

          -  Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or
             prednisone or their excipients

          -  Have a history of gastrointestinal disorders (medical disorders or extensive surgery)
             that may interfere with the absorption of the study agents

          -  Have a pre-existing condition that warrants long-term corticosteroid use in excess of
             study dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Efstathiou</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

